Hello JITC Readers,
Welcome to the last JITC Digest of 2022. It has been a busy and momentous year for the journal—we celebrated our 10th anniversary, we launched our peer review mentorship program, we surpassed 40,000 total citations, and we accepted more than 500 high-quality articles for publication.
Among the excellent articles that we published this year, our review series, “Imaging and Immunotherapy,” featured eight fantastic papers from leading voices from a multitude of backgrounds, including oncologists, imaging scientists, and radiologists. Explore this month’s special feature to catch up on the reviews on topics including novel imaging strategies, new approaches to conventional imaging such as artificial intelligence and radiomics, as well as special considerations for radiotherapy, immunotherapy, and imaging.
This month’s original research highlights include two innovative approaches to cell therapy, a role for RNA editing in limiting antitumor immunity with DNA methyltransferase inhibition, and the first quantitative systems pharmacology model for hepatocellular carcinoma.
Alvaro Haroun-Izquierdo and colleagues lay the groundwork for off-the-shelf cell therapies by developing a GMP-compliant protocol to reproducibly and robustly expand adaptive natural killer cells. Mechanisms of resistance to anti-BCMA CAR T cells in multiple myeloma are characterized by Nicolas Camviel et al.
Stephanie Gomez and colleagues provide rationale for combination inhibition of adenosine deaminase 1 and DNA methyltransferases to enhance lymphocyte infiltration and interferon sensitivity in ovarian cancer.
Finally, Richard J Sové et al conduct a virtual clinical trial in advanced hepatocellular carcinoma and identify candidate biomarkers predicting response to combination PD-1 and CTLA-4 blockade.
Wishing you all a wonderful holiday season and looking forward to the year ahead.
Best,
Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer
No comments:
Post a Comment